Fresenius Medical Care AG & Co. KGaA
A global provider of products and services for individuals with renal diseases.
FME | F
Overview
Corporate Details
- ISIN(s):
- DE0005785802 (+6 more)
- LEI:
- 549300CP8NY40UP89Q40
- Country:
- Germany
- Address:
- Else-Kröner-Str. 1, 61352 Bad Homburg vor der Höhe
- Industry:
- Medical and dental practice activities
Description
Fresenius Medical Care is a leading global provider of products and services for individuals with renal diseases. The company delivers comprehensive dialysis care to patients with chronic kidney failure through an extensive network of outpatient clinics. Its core services include in-center hemodialysis, home hemodialysis (HHD), and peritoneal dialysis (PD). As a vertically integrated company, it also develops, manufactures, and distributes a wide array of products essential for kidney replacement therapy. This portfolio includes advanced dialysis machines, dialyzers, water treatment systems, and related disposables. The company's offerings extend to home therapy systems, critical care solutions for acute blood purification and therapeutic apheresis, and specialized pediatric dialysis treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-12-05 23:39 |
Fresenius Medical Care AG & Co. KGaA: Helen Giza to take over as Chief Executiv…
|
English | 9.8 KB | ||
| 2022-12-05 23:34 |
Fresenius Medical Care AG & Co. KGaA: Ms. Helen Giza appointed as new CEO of th…
|
English | 6.0 KB | ||
| 2022-12-01 00:00 |
Declaration of Compliance December 2022
|
English | 238.5 KB | ||
| 2022-12-01 00:00 |
Entsprechenserklärung Dezember 2022
|
German | 228.3 KB | ||
| 2022-11-09 00:00 |
Q3 2022 Analyst Presentation
|
English | 1.1 MB | ||
| 2022-11-09 00:00 |
Q3 2022 Analyst Call
|
English | 713.0 KB | ||
| 2022-11-09 00:00 |
Q3 statement / Q3 financial report 2022
|
English | 696.3 KB | ||
| 2022-10-31 20:22 |
& Co. KGaA: Release according to Article 50 of the WpHG [the German Securities …
|
English | 3.6 KB | ||
| 2022-10-31 14:26 | German | 14.8 KB | |||
| 2022-10-30 17:35 |
Fresenius Medical Care AG & Co. KGaA revises financial outlook for full year 20…
|
English | 38.8 KB | ||
| 2022-10-30 17:30 |
Fresenius Medical Care AG & Co. KGaA extends net income target range for financ…
|
English | 5.4 KB | ||
| 2022-10-10 17:43 | English | 13.9 KB | |||
| 2022-08-09 00:00 |
Half-yearly financial report 2022
|
English | 589.6 KB | ||
| 2022-08-02 18:10 |
& Co. KGaA: Release according to Article 50 of the WpHG [the German Securities …
|
English | 3.7 KB | ||
| 2022-07-28 00:00 |
Q2 2022 Conference Call
|
English | 996.9 KB |
Automate Your Workflow. Get a real-time feed of all Fresenius Medical Care AG & Co. KGaA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Fresenius Medical Care AG & Co. KGaA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Fresenius Medical Care AG & Co. KGaA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-12-15 | Mazur-Hofsäß, Dr. Katarzyna | Board | Buy | None | 42,342.17 EUR |
| 2023-12-15 | Mazur-Hofsäß, Dr. Katarzyna | Board | Buy | None | 15,043.50 EUR |
| 2023-12-15 | Mazur-Hofsäß, Dr. Katarzyna | Board | Buy | None | 4,823.75 EUR |
| 2023-12-15 | Mazur-Hofsäß, Dr. Katarzyna | Board | Buy | None | 3,693.12 EUR |
| 2023-12-06 | Valle, William | Board | Other | None | 366,225.00 EUR |
| 2023-12-06 | Pring Giza, Helen | Board | Other | None | 264,360.84 EUR |
| 2023-12-06 | Maddux, Franklin W. | Board | Other | None | 246,309.94 EUR |
| 2023-12-06 | Mazur-Hofsäß, Dr. Katarzyna | Board | Other | None | 198,714.19 EUR |
| 2023-03-21 | Mazur-Hofsäß, Dr. Katarzyna | Board | Buy | None | 11,199.36 EUR |
| 2023-03-21 | Mazur-Hofsäß, Dr. Katarzyna | Board | Buy | None | 10,933.84 EUR |
Peer Companies
